Join

Compare · CANF vs ITOS

CANF vs ITOS

Side-by-side comparison of Can-Fite Biopharma Ltd (CANF) and iTeos Therapeutics Inc. (ITOS): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both companies sit in the Health Care sector. CANF focuses on Biotechnology: Pharmaceutical Preparations, while ITOS focuses on Biotechnology: Biological Products (No Diagnostic Substances).
  • ITOS is the larger of the two at $1.23B, about 185.1x CANF ($6.6M).
  • Over the past year, CANF is down 85.7% and ITOS is up 1.4% - ITOS leads by 87.1 points.
  • CANF has hit the wire 6 times in the past 4 weeks while ITOS has been quiet.
  • ITOS has more recent analyst coverage (9 ratings vs 2 for CANF).
PerformanceCANF-10.17%ITOS+1.40%
2026-03-16+0.00%2026-06-05
MetricCANFITOS
Company
Can-Fite Biopharma Ltd
iTeos Therapeutics Inc.
Price
$3.18+1.27%
$10.17+0.30%
Market cap
$6.6M
$1.23B
1M return
-10.67%
+0.39%
1Y return
-85.68%
+1.40%
Sector
Health Care
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Exchange
AMEX
NASDAQ
IPO
2020
News (4w)
6
0
Recent ratings
2
9
CANF

Can-Fite Biopharma Ltd

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver and inflammatory disease, COVID-19 and erectile dysfunction. The company's lead drug candidate CF101 (Piclidenoson), which is in Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops CF102 (Namodenoson) that is completed Phase II clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase II trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah-Tikva, Israel.

ITOS

iTeos Therapeutics Inc.

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.

Latest CANF

Latest ITOS